SCHEMBL400749

SCHEMBL400749

CON(Cc1ccccc1)OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.54
ALDH1A1 P00352 2/20 0.54
AOC3 Q16853 1/20 0.50
MAPK1 P28482 1/20 0.44
CARM1 Q86X55 1/20 0.43
PRMT6 Q96LA8 1/20 0.43
PRMT8 Q9NR22 1/20 0.43
CYP2C19 P33261 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
SLC6A2 P23975 1/20 0.42
HTR2A P28223 1/20 0.42
SLC6A4 P31645 1/20 0.42
ADRA1A P35348 1/20 0.42
OPRK1 P41145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7899272 0.98 TSHR (0.52) TSHRALDH1A1AOC3MAPK1CARM1
SCHEMBL10660626 0.80 TSHR (0.54) TSHRALDH1A1AOC3MAPK1CARM1
SCHEMBL28827127 0.79 NPC1 (0.43) ALDH1A1AOC3MAPK1NPC1RAB9A
SCHEMBL112375 0.78 TSHR (0.58) TSHRALDH1A1AOC3MAPK1CARM1
SCHEMBL5498059 0.78 TSHR (0.46) TSHRALDH1A1AOC3MAPK1CARM1
SCHEMBL3921323 0.76 CA2 (0.43) TSHRALDH1A1CYP2C19LMNACNR2
SCHEMBL9545622 0.76 TSHR (0.50) TSHRALDH1A1AOC3MAPK1CARM1
Hydrochloric Acid SCHEMBL31556140 0.76 TSHR (0.56) TSHRALDH1A1AOC3CARM1PRMT6
SCHEMBL828470 0.76 TAAR1 (0.58) AOC3SLC6A2SLC6A4ADRA1ASLC6A3
SCHEMBL6621098 0.76 TSHR (0.50) TSHRALDH1A1AOC3MAPK1CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543236-B1 METHOD FOR PREPARING AVIBACTAM INTERMEDIATE XINFA PHARMACEUTICAL CO LTD (CN) 2022-02-16 EP claimed
CN-107827817-B Method for synthesizing formamide derivative through molybdenum catalytic formylation reaction 湘潭大学 2020-03-13 CN claimed
US-10570132-B2 Process for preparing an intermediate for avibactam XINFA PHARMACEUTICAL CO., LTD (CN) 2020-02-25 US claimed
EP-3543236-A1 METHOD FOR PREPARING AVIBACTAM INTERMEDIATE Xinfa Pharmaceutical Co., Ltd (CN) 2019-09-25 EP claimed
US-20190263812-A1 PROCESS FOR PREPARING AN INTERMEDIATE FOR AVIBACTAM XINFA PHARMACEUTICAL CO., LTD (CN) 2019-08-29 US claimed
CN-103709161-B One-dimensional organic semiconductor nanowire with fluorescence and photoconduction dual response for organic amine gas as well as preparation method and application of nanowire CHINESE ACAD INST CHEMISTRY 2015-05-20 CN claimed
CN-103709161-A One-dimensional organic semiconductor nanowire with fluorescence and photoconduction dual response for organic amine gas as well as preparation method and application of nanowire CHINESE ACAD INST CHEMISTRY 2014-04-09 CN claimed
WO-2012033956-A1 COGNITION ENHANCING COMPOUNDS AND COMPOSITIONS, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2012-03-15 WO claimed
EP-1511730-B8 DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2009-04-08 EP claimed
US-20060128734-A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases FLOERSHEIMER ANDREAS 2006-06-15 US claimed
CN-1656073-A Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2005-08-17 CN claimed
EP-1511730-A2 DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2005-03-09 EP claimed
WO-2003099771-A2 DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2003-12-04 WO claimed
EP-1155001-A4 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES LION BIOSCIENCE AG (DE) 2003-05-28 EP claimed
EP-1155001-A1 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 2001-11-21 EP claimed
WO-2000050406-A1 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES LION BIOSCIENCE AG (DE) 2000-08-31 WO claimed
JP-6025163-A None JP disclosed
EP-4731689-A1 METHOD FOR THE PRODUCTION OF THERMOPLASTIC POLYOXAZOLIDINONE Covestro Deutschland AG (DE) 2026-04-29 EP disclosed
US-4089956-A 7-Acylamino-8-oxo-3-oxa-1-azabicyclo[4.2.0]octane-2-carboxylic acid derivatives and bactericidal compositions and use thereof SMITHKLINE CORPORATION (US) 1978-05-16 US disclosed
US-4072674-A FOR CEPHALOSPORIN CONGENERS SMITHKLINE CORPORATION (US) 1978-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10570132-B2 Process for preparing an intermediate for avibactam ODC1, UROD, STS TSHR 2379/4885ALDH1A1 2869/4885AOC3 115/4885
US-20190263812-A1 PROCESS FOR PREPARING AN INTERMEDIATE FOR AVIBACTAM ODC1, UROD, STS TSHR 2379/4885ALDH1A1 2869/4885AOC3 115/4885
US-20060128734-A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases UCK2, PRKDC, PRKACA TSHR 3952/4885ALDH1A1 3040/4885AOC3 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.